PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34699215-0	2021	Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer.	Paclitaxel	32-42	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	87-116	
27844290-7	2017	Moreover, enalapril (an ACE inhibitor) enhanced the mechanical allodynia induced by a low dose of paclitaxel.	Paclitaxel	98-108	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	24-27	
27844290-8	2017	Likewise, paclitaxel injection inhibited ACE activity and increased the expressions of B1 and B2 receptors and bradykinin-related peptides levels in peripheral tissue.	Paclitaxel	10-20	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	41-44	
32252517-4	2020	Scaffolds composed of fast, medium, and slow degrading Ace-DEX resulted in 14.1%, 2.9%, and 1.3% paclitaxel released per day.	Paclitaxel	97-107	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	55-58	
32252517-8	2020	Additionally, the acid-sensitive Ace-DEX scaffolds were shown to respond to the lower pH conditions associated with GBM tumors, releasing more paclitaxel in vivo when a tumor was present in contrast to nonacid sensitive PLA scaffolds.	Paclitaxel	143-153	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	33-36